TY -的T1 Gefapixant在两个随机剂量研究慢性咳嗽JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01615 -2019欧元SP - 1901615 AU -她a . Smith AU -迈克尔·m·基特盟-彼得Butera盟盟Steven a . Smith -是的李盟智徐金盟金伯利霍尔特AU - Shilpi森盟曼德尔r·谢尔AU -安东尼·p·福特Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/01/03/13993003.01615 - 2019. -抽象N2 -背景Gefapixant曾证明疗效在治疗难治性慢性咳嗽在高,每日剂量。目标当前调查探索gefapixant的疗效和耐受性,P2X3受体拮抗剂,使用剂量治疗慢性咳嗽的升级方法。材料和方法两个随机,双盲,安慰剂对照,交叉,剂量递增研究招募参与者与难治性慢性咳嗽。受试者被分配到接受提升剂gefapixant(研究1:50 - 200毫克,研究2:7.5 -50毫克)或安慰剂为16天,然后跨越惨败。主要终点是清醒咳嗽频率评估使用24 h动态咳嗽监测仪在基线和每个剂量的第四天。病人报告结果包括咳嗽严重视觉模拟量表(血管)和咳嗽严重日记(CSD)。结果在临床研究中,gefapixant≥30毫克剂量产生极大的改善咳嗽频率与安慰剂比较(术中,0.05);报道咳嗽严重措施改进类似的剂量。味觉干扰表现出不同的与剂量的关系,显然最大剂量≥150毫克。结论P2X3对抗gefapixant演示anti-tussive疗效和耐受性提高在低剂量比先前调查。长期的研究是必要的。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr Smith reports grants and personal fees from Merck Inc, during the conduct of the study; grants and personal fees from Glaxosmithkline, grants and personal fees from NeRRe Pharmaceuticals, grants and personal fees from Menlo, grants and personal fees from Bayer, personal fees from Boehringer Ingleheim, personal fees from Genentech, personal fees from Neomed, non-financial support from Vitalograph, personal fees from Cheisi, grants and personal fees from Afferent, personal fees from Bellus, grants and personal fees from Axalbion, personal fees from AstraZeneca, outside the submitted work; In addition, Dr Smith has a patent A method for generating output data licensed.Conflict of interest: Dr Kitt reports other from Merck/Afferent, during the conduct of the study; other from Merck/Afferent, outside the submitted work.Conflict of interest: Dr Butera reports other from Afferent Pharmaceuticals, Inc., during the conduct of the study; other from Afferent Pharmaceuticals, Inc., outside the submitted work; and I was an employee of Afferent Pharmaceuticals, Inc..Conflict of interest: Mr. Smith reports personal fees from Afferent Pharmaceuticals, during the conduct of the studyConflict of interest: Dr Li reports personal fees from Afferent/Merck & Co., Inc, during the conduct of the study.Conflict of interest: Dr Xu has nothing to disclose.Conflict of interest: Ms. Holt has nothing to disclose.Conflict of interest: Dr Sen has nothing to disclose.Conflict of interest: Dr sher reports personal fees from Afferent, personal fees from Merck, during the conduct of the study; and Consultant to Bellus, Bayer, NeRRe with clinical studies with Menlo and NeRRe.Conflict of interest: Dr Ford has nothing to disclose. ER -